Birdwatch Archive

Birdwatch Note Rating

2024-10-31 18:14:16 UTC - HELPFUL

Rated by Participant: 709191EAD5F29BD469F19280D75D63471DD28E51D6D87F49E4C58DE0E09B8933
Participant Details

Original Note:

False. GSK sold Intepirdine (RVT-101) to Axovant for $5m. It had some benefits in a phase IIb trial. A re-analysis found a larger effect. 1,315 patients enrolled in Phase III trial with the adjunct drug. The results was not replicated. 98% of alzheimers drugs fail. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198803/ https://www.alzforum.org/therapeutics/intepirdine

All Note Details

Original Tweet

All Information

  • noteId - 1746574570616959105
  • participantId -
  • raterParticipantId - 709191EAD5F29BD469F19280D75D63471DD28E51D6D87F49E4C58DE0E09B8933
  • createdAtMillis - 1730398456175
  • version - 2
  • agree - 0
  • disagree - 0
  • helpful - 0
  • notHelpful - 0
  • helpfulnessLevel - HELPFUL
  • helpfulOther - 0
  • helpfulInformative - 0
  • helpfulClear - 0
  • helpfulEmpathetic - 0
  • helpfulGoodSources - 1
  • helpfulUniqueContext - 0
  • helpfulAddressesClaim - 1
  • helpfulImportantContext - 1
  • helpfulUnbiasedLanguage - 0
  • notHelpfulOther - 0
  • notHelpfulIncorrect - 0
  • notHelpfulSourcesMissingOrUnreliable - 0
  • notHelpfulOpinionSpeculationOrBias - 0
  • notHelpfulMissingKeyPoints - 0
  • notHelpfulOutdated - 0
  • notHelpfulHardToUnderstand - 0
  • notHelpfulArgumentativeOrBiased - 0
  • notHelpfulOffTopic - 0
  • notHelpfulSpamHarassmentOrAbuse - 0
  • notHelpfulIrrelevantSources - 0
  • notHelpfulOpinionSpeculation - 0
  • notHelpfulNoteNotNeeded - 0
  • ratingsId - 1746574570616959105709191EAD5F29BD469F19280D75D63471DD28E51D6D87F49E4C58DE0E09B8933